Oligonucleotide Synthesis Market Industry Trends and Global Forecasts to 2035: by Application Area, Type of Product Synthesized, Type of Oligonucleotide Synthesized, Scale of Operation, Therapeutic Area, End-Users, Company Size and Key Geographical Regions

The global oligonucleotide synthesis market is estimated to grow from USD 4.8 billion in the current year to USD 13.5 billion by 2035, at a CAGR of 9.9% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Application Area

Research and Diagnostics
Therapeutics

Type of Product Synthesized

Active Pharmaceutical Ingredients
Finished Dosage Forms

Type of Oligonucleotide Synthesized

Antisense
DNA
siRNA
Other Oligonucleotides

Scale of Operation

Clinical
Commercial

Therapeutic Area

Cardiovascular Disorders
Genetic Disorders
Liver Disorders
Rare Diseases
Other Disorders

End-users

Pharmaceutical/Biopharmaceutical Companies
Academic And Research Institutes
Hospitals

Company Size

Small
Mid-sized
Large and Very Large

Key Geographical Regions

North America
Europe
Asia-Pacific
Rest of the World

Oligonucleotide Synthesis Market: Growth and Trends

Oligonucleotides are one of the fastest growing segments in the pharmaceutical industry. These molecules are extensively utilized in biopharmaceutical and biotechnology fields for various applications, including research, genetic testing, forensic analysis, and other analytical methods. Currently, researchers are investigating the potential of oligonucleotides as a pharmacological approach for the treatment of a myriad of disease indications. In addition, it is worth noting that close to 300 clinical trials have been registered across different geographical regions to evaluate various oligonucleotides for therapeutic purposes. As the oligonucleotide manufacturing industry advances, numerous automatic oligo synthesizers are being incorporated into large scale production for developing and producing oligonucleotide therapeutics. These synthesizers can execute steps, such as molecule synthesis, removal of protecting groups, purification, desalting and lyophilization, with increased efficiency. However, the challenges associated with oligonucleotide production, including extended timelines, lack of purification techniques, lack of expertise, and regulatory and compliance-related issues among the developers, have driven drug developers to outsource key operations. At present, over 110 oligonucleotide synthesis providers offer custom oligonucleotide synthesis, oligonucleotide modification and oligonucleotide purification services, which are intended for research, diagnostic and therapeutic applications. The growing oligonucleotide-based drugs pipeline, encouraging clinical trial results and extensive research activity in the domain, is likely to present lucrative market growth opportunities for custom / contract service providers, during the forecast period.

Oligonucleotide Synthesis Market: Key Insights

The report delves into the current state of the oligonucleotide synthesis market and identifies potential growth opportunities within the industry. Some key findings from the report include:

Presently, over 110 synthesis providers claim to have the necessary capabilities to offer oligonucleotide synthesis services; the majority of these firms are based in North America.
Stakeholders in this domain synthesize various types of oligonucleotides, across different scales of operations; close to 90% of the players offer purification services.

In pursuit of building a competitive edge in this field, stakeholders are actively upgrading their existing capabilities and adding new competencies in order to enhance their respective portfolios.
Close to 300 clinical trials (with over 75,000 enrolled patients) have been registered to investigate oligonucleotide based-therapeutic products, across different geographies.
Since 2017, several deals have been inked between various stakeholders engaged in this domain; acquisitions emerged as the most common type of partnership model.
To keep pace with the growing demand for oligonucleotides, companies have made elaborate investments to expand their existing capacities and capabilities; this trend is most pronounced in the US and China.

Several big pharma players have undertaken various initiatives, including partnerships, expansions and funding initiatives; 48% of such initiatives were focused on the development and manufacturing of RNAi oligonucleotides.
The global, installed oligonucleotide synthesis capacity is spread across various geographies; interestingly, more than 75% of the total capacity is installed at the facilities owned by large and very large players.
Given the growing complexity of APIs, the demand for oligonucleotides has upsurged; by 2035, it is anticipated to reach around 2,200 kilograms, across clinical and commercial scales.
Considering the wide array of applications of oligonucleotides and the continuous research efforts of stakeholders in this domain, the adoption of these modalities is poised to witness steady growth in the foreseeable future.
Driven by the increasing number of chronic indications (requiring novel personalized therapies) and ongoing research on oligonucleotide-based therapeutics, this market is anticipated to grow at a CAGR of 9.9%, till 2035.
Over 40% of the market is expected to be captured by revenues generated from manufacturing drugs for rare diseases; further, oligonucleotide synthesis market in China is likely to grow at a faster pace.

Oligonucleotide Synthesis Market: Key Segments

Currently, the Oligonucleotide Finished Dosage Form holds the Largest Share of the Oligonucleotide Synthesis Market

Based on the type of product synthesized, the market is segmented into active pharmaceutical ingredients and finished dosage forms. It is worth highlighting that the majority of the current oligonucleotide synthesis market is captured by oligonucleotide finished dosage form and this trend is likely to remain same in the coming decade.

Antisense Oligonucleotide is Likely to Dominate the Oligonucleotide Synthesis Market During the Forecast Period

Based on the type of oligonucleotide synthesized, the market is segmented into antisense, DNA, siRNA and other oligonucleotides. It is worth highlighting that siRNA and antisense oligonucleotides-based therapies are likely to grow at a relatively higher CAGR, during the forecast period. This can be attributed to the rising number of approved siRNA and antisense oligonucleotides-based therapies for various rare diseases, genetic disorders and other disorders.

By Scale of Operation, Commercial Scale is Likely to Capture the Larger Share of the Oligonucleotide Synthesis Market During the Forecast Period

Based on scales of operation, the market is segmented into clinical and commercial scale. It is worth highlighting that the commercial scale manufacturing will be the primary driver of the overall market in the coming decade.

Currently, Pharmaceutical and Biopharmaceutical Companies hold the Largest Share within the Oligonucleotide Synthesis Market

Based on end user, the market is segmented into pharmaceutical and biopharmaceutical companies, academic and research institutes, and hospitals. It is worth highlighting that the revenues generated from manufacturing of oligonucleotides by pharmaceutical and biopharmaceutical companies is expected to grow substantially in the coming decade as compared to other end-users.

By Company Size, Mid-Sized Companies are Likely to Grow at a Relatively Higher Pace During the Forecast Period

Based on company size, the market is segmented into small, mid-sized, and large and very large companies. It is worth highlighting that the majority of the current oligonucleotide synthesis market is captured by large and very large players.

Rare Diseases Segment Accounts for the Largest Share for the Oligonucleotide Synthesis Market

Based on therapeutic areas, the market is segmented into cardiovascular disorders, genetic disorders, liver disorders, rare diseases and other disorders. While rare diseases account for a relatively higher market share, it is worth highlighting that cardiovascular disorders segment is expected to witness substantial market growth in the coming years.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific and Rest of the World. It is worth highlighting that over the years, the market in Asia-Pacific is expected to grow at a higher CAGR.

Key Oligonucleotide Synthesis Market Players Profiled in the Report include:

Agilent Technologies
Ajinomoto Bio-Pharma Services
CordenPharma
Creative Biolabs
Ella Biotech
Eurofins Genomics
Future synthesis
Integrated DNA Technologies
Kaneka Eurogentec
LGC Biosearch Technologies
Microsynth
Nitto Avecia
Merck
Ribo Biotechnology
STA Pharmaceutical
Sumitomo Chemical
Thermo Fisher Scientific
TriLink Biotechnologies

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

Founder and Managing Director, BianoGMP
Co-Founder and Managing Director, Hanugen Therapeutics
Chief Scientific Officer and Managing Director, IBA Life Sciences
Chief Scientific Officer, Axolabs
Business Officer, SBS Genetech
Chem Lab Manager, Aptagen
Global Corporate Sales and Business Development, Invitek Diagnostics

Oligonucleotide Synthesis Market: Research Coverage

The report features an in-depth analysis of the oligonucleotide synthesis market, focusing on key market segments, including application area, type of product synthesized, type of oligonucleotide synthesized, scale of operation, therapeutic area, end-users, company size and key geographical regions.
The report analyzes various factors such as drivers, restraints, opportunities, and challenges affecting the market growth.
A comprehensive evaluation of companies involved in oligonucleotide synthesis, considering various parameters, such as year of establishment, company size (in terms of employee count), location of headquarters, location of oligonucleotide synthesis facilities, scale of operation (preclinical, clinical and commercial), type of oligonucleotide synthesized (antisense oligonucleotides, aptamers, DNA oligonucleotides, oligonucleotide probes, primers, RNA oligonucleotides and others), type of product synthesized (oligonucleotide API and finished dosage form / drug product), application area (research, diagnostic and therapeutic) and type of additional services offered (process development / method validation, analytical testing, custom synthesis, sequencing, modification, purification, fill-finish, quality assurance and control, and regulatory support).
A comprehensive competitive analysis of oligonucleotide synthesis providers, examining factors such as supplier strength (in terms of years of experience), service strength and number of oligonucleotide synthesis facilities.
In-depth profiles of key industry players engaged in oligonucleotide synthesis services, focusing on company overviews, financial information (if available), service portfolio, recent developments and an informed future outlook.
An insightful framework for the make-or-buy decision, emphasizing the key indicators and factors that affect sponsors and developers in determining whether to outsource oligonucleotide manufacturing or develop the means to carry it in-house.
Examination of completed, ongoing, and planned clinical studies based on parameters like trial registration year, trial status, trial phase, enrolled patient population, type of sponsor, most active industry players (in terms of number of trials conducted), study design, therapeutic area and key geographical regions.
An analysis of partnerships established in this sector, since 2014, based on several parameters, such as year of partnership, type of partnership, type of oligonucleotide, therapeutic area, application area and the most active players (in terms of the number of partnerships signed). It also provides the regional distribution of the companies involved in these agreements.
An examination of the different expansion efforts made by oligonucleotide synthesis providers in this field to enhance their manufacturing capabilities, since 2015. This analysis considers various factors, including the year of expansion, type of expansion, scale of operation, application area, amount invested, area of facility and location of expanded facility.
Assessment of the various oligonucleotide-focused manufacturing initiatives undertaken by big pharma players, based on several relevant parameters, such as number of initiatives, year of initiative, type of initiative, type of initiative, scale of operation, type of oligonucleotide manufactured, and amount invested.
Estimation of global oligonucleotides manufacturing capacity, derived from data provided by various industry stakeholders in the public domain. This analysis emphasizes the distribution of the available capacity on the basis of company size (small, mid-sized, and large and very large firms) and key geographical regions (North America, Europe and, Asia-Pacific and Rest of the World).
Informed estimates of the annual clinical demand for oligonucleotide therapeutics (in terms of target patient population in ongoing and planned clinical trials of oligonucleotide therapeutics). It also includes the commercial demand for oligonucleotides, taking into account the top 12 oligonucleotide-based therapies and phase III drugs, based on various relevant parameters, such as target patient population, dosing frequency and dose strength of the abovementioned products.

Key Questions Answered in this Report

How many companies are currently engaged in this market?
Which are the leading companies in this market?
What kind of partnership models are commonly adopted by industry stakeholders?
What kinds of expansion initiatives have been undertaken by industry stakeholders?
What is the current annual demand for oligonucleotides?
What are the factors that are likely to influence the evolution of this market?
What is current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

Additional Benefits

Complimentary PPT Insights Packs
Complimentary Excel Data Packs for all Analytical Modules in the Report
10% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older

1. PREFACE

1.1. Scope of the Report 1.2. Research Methodology 1.3. Key Questions Answered 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

2.1. Chapter Overview

3. INTRODUCTION

3.1. Context and Background 3.2. Overview of Oligonucleotide-based Products 3.3. Types of Oligonucleotides 3.3.1. Antisense Oligonucleotides 3.3.2. Aptamers 3.3.3. miRNA 3.3.4. shRNA 3.3.5. siRNA 3.3.6. Other Oligonucleotides 3.4.Custom Synthesis of Oligonucleotides 3.4.1. Process Development and Characterization 3.4.2. Analytical Method Development 3.4.3. Method Validation and Testing 3.4.4. Quality Control and Quality Assurance 3.4.5. Challenges Associated with Custom Synthesis of Oligonucleotides 3.5. Chemical Modification of Oligonucleotides 3.5.1. Backbone Modification 3.5.2. Sugar Ring Modification 3.6. Purification of Oligonucleotides 3.6.1. Desalting 3.6.2. Cartridge Purification 3.6.3. Polyacrylamide Gel Electrophoresis (PAGE) 3.6.4. High Performance Liquid Chromatography (HPLC) 3.7. Outsourcing Oligonucleotide Manufacturing 3.7.1. Need for Outsourcing 3.7.2. Commonly Outsourced Operations 3.7.3. Advantages of Outsourcing Manufacturing Operations 3.7.4. Guidelines for Selecting a Service Provider 3.8. Growth Drivers and Roadblocks to Oligonucleotide Manufacturing 3.9. Recent Developments and Upcoming Trends

4. MARKET LANDSCAPE: OLIGONUCLEOTIDE MANUFACTURERES (RESEARCH AND DIAGNOSTIC APPLICATIONS)

4.1. Chapter Overview 4.2. Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Overall Market Landscape 4.2.1. Analysis by Year of Establishment 4.2.2. Analysis by Company Size 4.2.3. Analysis by Scale of Operation 4.2.4. Analysis by Geographical Location 4.2.5. Analysis by Location of Manufacturing Facilities 4.2.6. Analysis by Regulatory Accreditations / Certifications Received 4.2.7. Analysis by Type of Oligonucleotide Manufactured 4.2.8. Analysis by Type of Offering 4.2.9. Analysis by Type of Manufacturing Service(s) Offered 4.2.10. Analysis by Type of Modification(s) Offered 4.2.11. Analysis by Type of Purification Method(s) Used

5. MARKET LANDSCAPE: OLIGONUCLEOTIDE MANUFACTURERES (THERAPEUTIC APPLICATIONS)

5.1. Chapter Overview 5.2. Oligonucleotide Manufacturers Focused on Therapeutic Applications: Overall Market Landscape 5.2.1. Analysis by Year of Establishment 5.2.2. Analysis by Company Size 5.2.3. Analysis by Scale of Operation 5.2.4. Analysis by Geographical Location 5.2.5. Analysis by Location of Manufacturing Facilities 5.2.6. Analysis by Regulatory Accreditations / Certifications 5.2.7. Analysis by Type of Oligonucleotide Manufactured 5.2.8. Analysis by Type of Offering 5.2.9. Analysis by Type of Manufacturing Service(s) Offered 5.2.10. Analysis by Type of Modification(s) Offered 5.2.11. Analysis by Type of Purification Method(s) Used

6. COMPANY COMPETITIVENESS ANALYSIS: OLIGONUCLEOTIDE MANUFACTURES (RESEARCH AND DIAGNOSTIC APPLICATIONS)

6.1. Chapter Overview 6.2. Assumptions / Key Parameters 6.3. Methodology 6.4. Company Competitiveness Analysis: Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications 6.4.1. Oligonucleotide Manufacturers in North America 6.4.2. Oligonucleotide Manufacturers in Europe 6.4.3. Oligonucleotide Manufacturers in Asia-Pacific

7. COMPANY COMPETITIVENESS ANALYSIS: OLIGONUCLEOTIDE MANUFACTURERS (THERAPEUTIC APPLICATIONS)

7.1. Chapter Overview 7.2. Assumptions / Key Parameters 7.3. Methodology 7.4. Company Competitiveness Analysis: Oligonucleotide Manufacturers Focused on Therapeutic Applications 7.4.1. Oligonucleotide Manufacturers in North America 7.4.2. Oligonucleotide Manufacturers in Europe 7.4.3. Oligonucleotide Manufacturers in Asia-Pacific

8. COMPANY PROFILES: OLIGONUCLEOTIDE MANUFACTURERS (RESEARCH AND DIAGNOSTIC APPLICATIONS)

8.1. Chapter Overview 8.2. North America 8.2.1. Ajinomoto Bio-Pharma Services 8.2.1.1. Company Overview 8.2.1.2. Financial Information 8.2.1.3. Service Portfolio 8.2.1.4. Manufacturing Facilities and Capabilities 8.2.1.5. Recent Developments and Future Outlook 8.2.2. Integrated DNA Technologies 8.2.2.1. Company Overview 8.2.2.2. Service Portfolio 8.2.2.3. Manufacturing Facilities and Capabilities 8.2.2.4. Recent Developments and Future Outlook 8.2.3. Sigma Aldrich 8.2.3.1. Company Overview 8.2.3.2. Service Portfolio 8.2.3.3. Manufacturing Facilities and Capabilities 8.2.3.4. Recent Developments and Future Outlook 8.2.4. Thermo Fisher Scientific 8.2.4.1. Company Overview 8.2.4.2. Financial Information 8.2.4.3. Service Portfolio 8.2.4.4. Manufacturing Facilities and Capabilities 8.2.4.5. Recent Developments and Future Outlook 8.3. Europe 8.3.1. BioSpring 8.3.1.1. Company Overview 8.3.1.2. Service Portfolio 8.3.1.3. Manufacturing Facilities and Capabilities 8.3.1.4. Recent Developments and Future Outlook 8.3.2. Kaneka Eurogentec 8.3.2.1. Company Overview 8.3.2.2. Financial Information 8.3.2.3. Service Portfolio 8.3.2.4. Manufacturing Facilities and Capabilities 8.3.2.5. Recent Developments and Future Outlook 8.3.3. Microsynth 8.3.3.1. Company Overview 8.3.3.2. Service Portfolio 8.3.3.3. Manufacturing Facilities and Capabilities 8.3.3.4. Recent Developments and Future Outlook 8.4. Asia-Pacific and RoW 8.4.1. Sumitomo Chemical 8.4.1.1. Company Overview 8.4.1.2. Financial Information 8.4.1.3. Service Portfolio 8.4.1.4. Manufacturing Facilities and Capabilities 8.4.1.5. Recent Developments and Future Outlook

9. COMPANY PROFILES: OLIGONUCLEOTIDE MANUFACTURERS (THERAPEUTIC APPLICATIONS)

9.1. Chapter Overview 9.2. North America 9.2.1. Agilent Technologies 9.2.1.1. Company Overview 9.2.1.2. Financial Information 9.2.1.3. Service Portfolio 9.2.1.4. Manufacturing Facilities and Capabilities 9.2.1.5. Recent Developments and Future Outlook 9.2.2. Nitto Denko Avecia 9.2.2.1. Company Overview 9.2.2.2. Financial Information 9.2.2.3. Service Portfolio 9.2.2.4. Manufacturing Facilities and Capabilities 9.2.2.5. Recent Developments and Future Outlook 9.2.3. TriLink Biotechnologies 9.2.3.1. Company Overview 9.2.3.2. Financial Information 9.2.3.3. Service Portfolio 9.2.3.4. Manufacturing Facilities and Capabilities 9.2.3.5. Recent Developments and Future Outlook 9.3. Europe 9.3.1. CordenPharma 9.3.1.1.Company Overview 9.3.1.2. Service Portfolio 9.3.1.3. Manufacturing Facilities and Capabilities 9.3.1.4. Recent Developments and Future Outlook 9.3.2. LGC, Biosearch Technologies 9.3.2.1. Company Overview 9.3.2.2. Service Portfolio 9.3.2.3. Manufacturing Facilities and Capabilities 9.3.2.4. Recent Developments and Future Outlook 9.3.3. Lonza 9.3.3.1. Company Overview 9.3.3.2. Financial Information 9.3.3.3. Service Portfolio 9.3.3.4. Manufacturing Facilities and Capabilities 9.3.3.5. Recent Developments and Future Outlook 9.4. Asia-Pacific 9.4.1. STA Pharmaceutical 9.4.1.1. Company Overview 9.4.1.2. Financial Information 9.4.1.3. Service Portfolio 9.4.1.4. Manufacturing Facilities and Capabilities 9.4.1.5. Recent Developments and Future Outlook

10. MAKE VERSUS BUY DECISION FRAMEWORK

10.1. Chapter Overview 10.2. Assumptions and Key Parameters 10.3. Oligonucleotide Manufacturers: Make versus Buy Decision Making 10.3.1. Scenario 1 10.3.2. Scenario 2 10.3.3. Scenario 3 10.3.4. Scenario 4 10.4. Concluding Remarks

11. BIG PHARMA INITIATIVES

11.1. Chapter Overview 11.2. List of Oligonucleotide Manufacturing Initiatives 11.2.1. Analysis by Year of Initiative 11.2.2. Analysis by Type of Initiative 11.2.3. Analysis by Type of Oligonucleotide

12. PARTNERSHIPS AND COLLABORATIONS

12.1. Chapter Overview 12.2. Partnership Models 12.3. Oligonucleotide Manufacturers: Recent Partnerships and Collaborations 12.3.1. Analysis by Year of Partnership 12.3.2. Analysis by Type of Partnership 12.3.3. Analysis by Type of Partner 12.3.4. Most Active Players: Analysis by Number of Partnerships 12.3.5. Analysis by Region 12.3.5.1. Most Active Players: Analysis by Number of Partnerships and Region 12.3.5.2. Intercontinental and Intracontinental Agreements 12.4. Oligonucleotide Manufacturers: Mergers / Acquisitions 12.4.1. Analysis by Year of Merger / Acquisition 12.4.2. Analysis by Type of Acquisition 12.4.3.Key Value Drivers

13. RECENT EXPANSIONS

13.1. Chapter Overview 13.2. Oligonucleotide Manufacturers: Recent Expansions 13.2.1. Analysis by Year of Expansion 13.2.2. Analysis by Type of Expansion 13.2.3. Analysis by Purpose of Expansion 13.2.4. Analysis by Location of Facility 13.2.5. Analysis by Expanded Facility Area 13.2.6. Analysis by Scale of Operation 13.3.7. Most Active Players: Analysis by Number of Expansions 13.3.8. Analysis by Region 13.3.8.1. Continent-wise Distribution 13.3.8.2.Country-wise Distribution

14. LIKELY PARTNER ANALYSIS

14.1. Chapter Overview 14.2. Scoring Criteria and Key Assumptions 14.3. Scope and Methodology 14.4. Potential Strategic Partners 14.4.1. Likely Partners for Antisense Oligonucleotides Manufacturers 14.4.2. Likely Partners for siRNA Therapeutics Manufacturers 14.4.3. Likely Partners for miRNA Therapeutics Manufacturers 14.4.4. Likely Partners for shRNA and sshRNA Therapeutics Manufacturers

15. CLINICAL TRIAL ANALYSIS

15.1. Chapter Overview 15.2. Scope and Methodology 15.3. Oligonucleotide-based Products: Clinical Trial Analysis 15.3.1. Analysis by Trial Registration Year 15.3.2. Analysis by Trial Phase 15.3.3. Analysis by Type of Oligonucleotide 15.3.4. Analysis by Trial Phase and Type of Oligonucleotide 15.3.5. Analysis by Trial Recruitment Status 15.3.6. Analysis by Trial Focus Area 15.3.7.Analysis by Study Design 15.3.8. Geographical Analysis by Number of Clinical Trials 15.3.9. Geographical Analysis by Enrolled Patient Population 15.3.10. Analysis by Type of Sponsor / Collaborator 15.3.11. Most Active Players: Analysis by Number of Registered Trials

16. CAPACITY ANALYSIS

16.1. Chapter Overview 16.2. Key Assumptions and Methodology 16.3. Oligonucleotide Manufacturers: Global Annual Capacity 16.3.1. Analysis by Size of Manufacturer 16.3.2. Analysis by Scale of Operation 16.3.3. Analysis by Location of Manufacturing Facility

17. DEMAND ANALYSIS

17.1. Chapter Overview 17.2. Key Assumptions and Methodology 17.3. Global Demand for Oligonucleotide Manufacturing 17.3.1. Global Commercial Demand for Oligonucleotide Manufacturing 17.3.1.1. Analysis by Type of Oligonucleotide 17.3.1.2. Analysis by Target Therapeutic Area 17.3.1.3. Analysis by Region 17.3.2. Global Clinical Demand for Oligonucleotide Manufacturing 17.3.2.1. Analysis by Type of Oligonucleotide 17.3.2.2. Analysis by Phase of Development 17.3.2.3. Analysis by Target Therapeutic Area 17.3.2.4. Analysis by Region 17.4. Demand and Supply Analysis 17.4.1. Scenario 1 17.4.2. Scenario 2 17.4.3. Scenario 3

18. MARKET SIZING AND OPPORTUNITY ANALYSIS

18.1. Chapter Overview 18.2. Key Assumptions and Forecast Methodology 18.3. Global Oligonucleotide Contract Manufacturing Market, till 2030 18.4. Oligonucleotide Manufacturing Market: Analysis by Application Area, till 2030 18.4.1. Oligonucleotide Manufacturing Market for Research and Diagnostics Applications, till 2030 18.4.2. Oligonucleotide Manufacturing Market for Therapeutics Applications, till 2030 18.4.2.1 Oligonucleotide Manufacturing Market: Analysis by Type of Oligonucleotide Manufactured, till 2030 18.4.2.1.1. Oligonucleotide Manufacturing Market for Antisense Oligonucleotides, till 2030 18.4.2.1.2. Oligonucleotide Manufacturing Market for miRNA, till 2030 18.4.2.1.3. Oligonucleotide Manufacturing Market for DNA Oligonucleotides, till 2030 18.4.2.1.4. Oligonucleotide Manufacturing Market for siRNA, till 2030 18.4.2.1.5. Oligonucleotide Manufacturing Market for Phosphorothioate Oligonucleotides, till 2030 18.4.2.1.6. Oligonucleotide Manufacturing Market for Decoy Oligonucleotides, till 2030 18.4.2.2. Oligonucleotide Manufacturing Market: Analysis by Scale of Operation, till 2030 18.4.2.2.1. Oligonucleotide Manufacturing Market for Clinical Scale Operations, till 2030 18.4.2.2.2. Oligonucleotide Manufacturing Market for Commercial Scale Operations, till 2030 18.4.2.3. Oligonucleotide Manufacturing Market: Analysis by Type of Operation, till 2030 18.4.2.3.1. Oligonucleotide Manufacturing Market for Active Pharmaceutical Ingredients, till 2030 18.4.2.3.2. Oligonucleotide Manufacturing Market for Finished Dosage Form, till 2030 18.4.2.4. Oligonucleotide Manufacturing Market: Analysis by Purpose of Production, till 2030 18.4.2.4.1. Oligonucleotide Manufacturing Market for In-House Operations, till 2030 18.4.2.4.2. Oligonucleotide Manufacturing Market for Outsourced Operations, till 2030 18.4.2.5. Oligonucleotide Manufacturing Market: Analysis by Target Therapeutic Area, till 2030 18.4.2.5.1. Oligonucleotide Manufacturing Market for Cardiovascular Disorders, till 2030 18.4.2.5.2. Oligonucleotide Manufacturing Market for CNS Disorders, till 2030 18.4.2.5.3. Oligonucleotide Manufacturing Market for Genetic Disorders, till 2030 18.4.2.5.4. Oligonucleotide Manufacturing Market for Hematological Diseases, till 2030 18.4.2.5.5. Oligonucleotide Manufacturing Market for Infectious Diseases, till 2030 18.4.2.5.6. Oligonucleotide Manufacturing Market for Metabolic Disorders, till 2030 18.4.2.5.7. Oligonucleotide Manufacturing Market for Neuromuscular Disorders, till 2030 18.4.2.5.8. Oligonucleotide Manufacturing Market for Oncological Disorders, till 2030 18.4.2.5.9. Oligonucleotide Manufacturing Market for Ophthalmic Disorders, till 2030 18.4.2.5.10. Oligonucleotide Manufacturing Market for Other Disorders, till 2030 18.4.2.6. Oligonucleotide Manufacturing Market: Analysis by Size of Manufacturer, till 2030 18.4.2.6.1. Oligonucleotide Manufacturing Market for Small Companies, till 2030 18.4.2.6.2. Oligonucleotide Manufacturing Market for Mid-sized Companies, till 2030 18.4.2.6.3. Oligonucleotide Manufacturing Market for Large and Very Large Companies, till 2030 18.4.2.7. Oligonucleotide Manufacturing Market: Analysis by Geography, till 2030 18.4.2.7.1. Oligonucleotide Manufacturing Market in North America, till 2030 18.4.2.7.2. Oligonucleotide Manufacturing Market in Europe, till 2030 18.4.2.7.3. Oligonucleotide Manufacturing Market in Asia-Pacific and Rest of the World, till 2030

19. IMPACT OF COVID-19 PANDEMIC ON OLIGONUCLEOTIDE SYNTHESIS MARKET

19.1. Chapter Overview 19.2. Impact of COVID-19 on Oligonucleotide Synthesis Market 19.2.1. Impact on Future Oligonucleotide Market Opportunity 19.3. Recuperative Strategies for Businesses 19.3.1. Strategies for Implementation in the Short / Mid Term 19.3.2. Strategies for Implementation in the Long Term

20. SWOT ANALYSIS

20.1. Chapter Overview 20.2. Comparison of SWOT Factors

21. SURVEY ANALYSIS

21.1. Chapter Overview 21.2. Overview of Respondents 21.2.1. Analysis by Seniority Level of Respondents 21.3.Analysis of Survey Insights 21.3.1. Analysis by Type of Offering 21.3.2. Analysis by Application 21.3.3.Analysis by Installed Manufacturing Capacity 21.3.4. Analysis by Location of Manufacturing Facility 21.3.5. Analysis by Extent of Outsourcing 21.3.6.Analysis by Current Market Opportunity

22.EXECUTIVE INSIGHTS

22.1. Chapter Overview 22.2. Hanugen Therapeutics 22.2.1. Company Snapshot 22.2.2. Interview Transcript: Arun Shastry, Co-Founder and Managing Director 22.3. Axolabs 22.3.1. Company Snapshot 22.3.2. Interview Transcript: Hans-Peter Vornlocher, Managing Director 22.4. IBA Life Sciences 22.4.1. Company Snapshot 22.4.2. Interview Transcript: Joachim Bertram, Chief Scientific Officer and Managing Director 22.5. BianoScience 22.5.1. Company Snapshot 22.5.2. Interview Transcript: Tobias Pohlmann, Founder and Managing Director

23. CONCLUDING REMARKS

23.1. Chapter Overview

24. APPENDIX 1: TABULATED DATA25. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

LIST OF FIGURES

Figure 2.1 Executive Summary: Overall Market Landscape of Oligonucleotide Manufacturers focused on Research and Diagnostic Applications Figure 2.2 Executive Summary: Overall Market Landscape of Oligonucleotide Manufacturers focused on Therapeutic Applications Figure 2.3 Executive Summary: Big Pharma Initiatives Figure 2.4 Executive Summary: Partnerships and Collaborations Figure 2.5 Executive Summary: Recent Expansions Figure 2.6 Executive Summary: Clinical Trial Analysis Figure 2.7 Executive Summary: Capacity Analysis Figure 2.8 Executive Summary: Demand Analysis Figure 2.9 Executive Summary: Market Sizing and Opportunity Analysis Figure 3.1 Classification of Oligonucleotides Figure 3.2 Steps Involved in the Manufacturing of Oligonucleotides Figure 3.3 Types of Chemical Modifications of Oligonucleotides Figure 3.4 Types of Purification Methods Used for Oligonucleotides Figure 3.5 Types of Standalone Service Providers Figure 3.6 Services Offered by Oligonucleotide Manufacturers Figure 3.7 Guidelines for Selecting an Oligonucleotide Manufacturer Figure 3.8 Growth Drivers and Roadblocks to Oligonucleotide Manufacturing Figure 4.1 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Year of Establishment Figure 4.2 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Company Size Figure 4.3 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Scale of Operation Figure 4.4 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Company Size and Scale of Operation Figure 4.5 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Headquarters Figure 4.6 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Manufacturing Facilities (Country-wise) Figure 4.7 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Regulatory Accreditations / Certifications Received Figure 4.8 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Oligonucleotide Manufactured Figure 4.9 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Offering Figure 4.10 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Company Size and Type of Offering Figure 4.11 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Oligonucleotide Manufactured and Type of Offering (Custom Synthesis) Figure 4.12 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Year of Establishment, Company Size and Type of Offering Figure 4.13 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Manufacturing Service(s) Offered Figure 4.14 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Modification(s) Offered Figure 4.15 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Purification Method(s) Used Figure 5.1 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Year of Establishment Figure 5.2 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Company Size Figure 5.3 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Scale of Operation Figure 5.4 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Company Size and Scale of Operation Figure 5.5 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Location of Headquarters (Region-wise) Figure 5.6 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Location of Manufacturing Facilities (Country-wise) Figure 5.7 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Regulatory Accreditations / Certifications Received Figure 5.8 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Oligonucleotide Manufactured Figure 5.9 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Offering Figure 5.10 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Company Size and Type of Offering Figure 5.11 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Oligonucleotide Manufactured and Type of Offering Figure 5.12 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Year of Establishment, Company Size and Type of Offering Figure 5.13 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Manufacturing Service(s) Offered Figure 5.14 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Modification(s) Offered Figure 5.15 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Purification Method(s) Used Figure 6.1 Company Competitiveness: Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications in North America Figure 6.2 Company Competitiveness: Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications in Europe Figure 6.3 Company Competitiveness: Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications in Asia-Pacific Figure 7.1 Company Competitiveness: Oligonucleotide Manufacturers Focused on Therapeutic Applications in North America Figure 7.2 Company Competitiveness: Oligonucleotide Manufacturers Focused on Therapeutic Applications in Europe Figure 7.3 Company Competitiveness: Oligonucleotide Manufacturers Focused on Therapeutic Applications in Asia-Pacific and Rest of the World Figure 8.1 Ajinomoto Group: Annual Revenues (JPY Billion) Figure 8.2 Thermo Fisher Scientific: Annual Revenues (USD Billion) Figure 8.3 Kaneka Group: Annual Revenues (JPY Billion) Figure 8.4 Sumitomo Chemical: Annual Revenues (JPY Billion) Figure 9.1 Agilent Technologies: Annual Revenues (USD Billion) Figure 9.2 Nitto Denko Avecia: Annual Revenues (USD Billion) Figure 9.3 Trilink Biotechnologies: Annual Revenues (USD Billion) Figure 9.4 Lonza: Annual Revenues (CHF Billion) Figure 9.5 STA Pharmaceutical: Annual Revenues (RMB Billion) Figure 10.1 Make versus Buy Decision Making Framework Figure 10.2 Make versus Buy Decision Making: Possible Scenario Descriptions Figure 11.1 Big Pharma Initiatives: Cumulative Distribution by Year of Initiative Figure 11.2 Big Pharma Initiatives: Distribution by Type of Initiative Figure 11.3 Big Pharma Initiatives: Distribution by Type of Oligonucleotide Manufactured Figure 12.1 Partnerships and Collaborations: Cumulative Distribution by Year of Partnership, since 2014 Figure 12.2 Partnerships and Collaborations: Distribution by Type of Partnership Figure 12.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership Figure 12.4 Partnerships and Collaborations: Distribution by Type of Partner Figure 12.5 Most Active Players: Distribution by Number of Partnerships Figure 12.6 Most Active Players: Country-wise Distribution by Number of Partnerships Figure 12.7 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution Figure 12.8 Mergers and Acquisitions: Distribution by Year of Merger / Acquisition Figure 12.9 Mergers and Acquisitions: Distribution by Type of Acquisition Figure 12.10 Mergers and Acquisitions: Key Value Drivers Figure 13.1 Recent Expansions: Distribution by Year of Expansion, since 2016 Figure 13.2 Recent Expansions: Distribution by Type of Expansion Figure 13.3 Recent Expansions: Distribution by Purpose of Expansion and Type of Expansion Figure 13.4 Recent Expansions: Distribution by Location of Facility Figure 13.5 Recent Expansions: Distribution by Type of Expansion and Location of Facility Figure 13.6 Recent Expansions: Distribution by Expanded Facility Area (Sq ft) Figure 13.7 Recent Expansions: Distribution by Scale of Operation Figure 13.8 Most Active Players: Distribution by Number of Expansions Figure 13.9 Recent Expansions: Year-wise Trend by Geography, since 2016 Figure 13.10 Recent Expansions: Distribution by Geography Figure 15.1 Clinical Trial Analysis: Methodology Used for Shortlisting Trials Figure 15.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, since 2013 Figure 15.3 Clinical Trial Analysis: Distribution by Trial Phase Figure 15.4 Clinical Trial Analysis: Distribution by Type of Oligonucleotide Figure 15.5 Clinical Trial Analysis: Distribution by Trial Phase and Type of Oligonucleotide Figure 15.6 Clinical Trial Analysis: Distribution by Trial Registration Year and Type of Oligonucleotide, since 2013 Figure 15.7 Clinical Trial Analysis: Distribution by Trial Recruitment Status Figure 15.8 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Recruitment Status Figure 15.9 Clinical Trial Analysis: Most Popular Keywords Figure 15.10 Clinical Trial Analysis: Distribution by Study Design Figure 15.11 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials Figure 15.12 Clinical Trial Analysis: Geographical Distribution by Trial Registration Year, since 2012 Figure 15.13 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population Figure 15.14 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year and Enrolled Patient Population, since 2012 Figure 15.15 Clinical Trial Analysis: Geographical Distribution by Trial Registration Year and Trial Recruitment Status Figure 15.16 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator Figure 15.17 Most Active Industry Players: Distribution by Number of Trials Registered Figure 15.18 Most Active Non-Industry Players: Distribution by Number of Trials Registered Figure 16.1 Global, Annual Oligonucleotide Manufacturing Capacity: Distribution by Size of Manufacturer (Kilograms) Figure 16.2 Global, Annual Oligonucleotide Manufacturing Capacity: Distribution by Range of Annual Capacity Figure 16.3 Global, Annual Oligonucleotide Manufacturing Capacity: Distribution by Scale of Operation (Kilograms) Figure 16.4 Global, Annual Oligonucleotide Manufacturing Capacity: Distribution by Location of Manufacturing Facility (Kilograms) Figure 17.1 Global Demand for Oligonucleotide Manufacturing (Kilograms) Figure 17.2 Global, Commercial Demand for Oligonucleotide Manufacturing (Kilograms) Figure 17.3 Global, Commercial Demand for Oligonucleotide Manufacturing: Distribution by Type of Oligonucleotide (Kilograms) Figure 17.4 Global, Commercial Demand for Oligonucleotide Manufacturing: Distribution by Target Therapeutic Area (Kilograms) Figure 17.5 Global, Commercial Demand for Oligonucleotide Manufacturing: Distribution by Geography (Kilograms) Figure 17.6 Global, Clinical Demand for Oligonucleotide Manufacturing (Kilograms) Figure 17.7 Global, Clinical Demand for Oligonucleotide Manufacturing: Distribution by Type of Oligonucleotide (Kilograms) Figure 17.8 Global, Clinical Demand for Oligonucleotide Manufacturing: Distribution by Phase of Development (Kilograms) Figure 17.9 Global, Clinical Demand for Oligonucleotide Manufacturing: Distribution by Target Therapeutic Area (Kilograms) Figure 17.10 Global, Clinical Demand for Oligonucleotide Manufacturing: Distribution by Geography (Kilograms) Figure 17.11 Global Oligonucleotide Manufacturing: Demand and Supply (Scenario 1), till 2030 Figure 17.12 Global Oligonucleotide Manufacturing: Demand and Supply (Scenario 2), till 2030 Figure 17.13 Global Oligonucleotide Manufacturing: Demand and Supply (Scenario 3), till 2030 Figure 18.1 Global Oligonucleotide Contract Manufacturing Market, till 2030 (USD Million) Figure 18.2 Oligonucleotide Manufacturing Market for Research and Diagnostics Applications, till 2030 (USD Million) Figure 18.3 Oligonucleotide Manufacturing Market for Therapeutics Applications, till 2030 (USD Million) Figure 18.4 Oligonucleotide Manufacturing Market: Distribution by Type of Oligonucleotide Manufactured, till 2030 Figure 18.5 Oligonucleotide Manufacturing Market for Antisense Oligonucleotides, till 2030 (USD Million) Figure 18.6 Oligonucleotide Manufacturing Market for miRNA, till 2030 (USD Million) Figure 18.7 Oligonucleotide Manufacturing Market for DNA Oligonucleotides, till 2030 (USD Million) Figure 18.8 Oligonucleotide Manufacturing Market for siRNA, till 2030 (USD Million) Figure 18.9 Oligonucleotide Manufacturing Market for Phosphorothioate Oligonucleotides, till 2030 (USD Million) Figure 18.10 Oligonucleotide Manufacturing Market for Decoy Oligonucleotides, till 2030 (USD Million) Figure 18.11 Oligonucleotide Manufacturing Market for Clinical Scale Operations, till 2030 (USD Million) Figure 18.12 Oligonucleotide Manufacturing Market for Commercial Scale Operations, till 2030 (USD Million) Figure 18.13 Oligonucleotide Manufacturing Market for Active Pharmaceutical Ingredients, till 2030 (USD Million) Figure 18.14 Oligonucleotide Manufacturing Market for Finished Dosage Form, till 2030 (USD Million) Figure 18.15 Oligonucleotide Manufacturing Market for In-house Operations, till 2030 (USD Million) Figure 18.16 Oligonucleotide Manufacturing Market for Outsourced Operations, till 2030 (USD Million) Figure 18.17 Oligonucleotide Manufacturing Market: Distribution by Target Therapeutic Area, 2025 and 2030 (USD Million) Figure 18.18 Oligonucleotide Manufacturing Market for Cardiovascular Disorders, till 2030 (USD Million) Figure 18.19 Oligonucleotide Manufacturing Market for CNS Disorders, till 2030 (USD Million) Figure 18.20 Oligonucleotide Manufacturing Market for Genetic Disorders, till 2030 (USD Million) Figure 18.21 Oligonucleotide Manufacturing Market for Hematological Diseases, till 2030 (USD Million) Figure 18.22 Oligonucleotide Manufacturing Market for Infectious Diseases, till 2030 (USD Million) Figure 18.23 Oligonucleotide Manufacturing Market for Metabolic Disorders, till 2030 (USD Million) Figure 18.24 Oligonucleotide Manufacturing Market for Neuromuscular Disorders, till 2030 (USD Million) Figure 18.25 Oligonucleotide Manufacturing Market for Oncological Disorders, till 2030 (USD Million) Figure 18.26 Oligonucleotide Manufacturing Market for Ophthalmic Disorders, till 2030 (USD Million) Figure 18.27 Oligonucleotide Manufacturing Market for Other Therapeutic Areas, till 2030 (USD Million) Figure 18.28 Oligonucleotide Manufacturing Market for Small Companies, till 2030 (USD Million) Figure 18.29 Oligonucleotide Manufacturing Market for Mid-sized Companies, till 2030 (USD Million) Figure 18.30 Oligonucleotide Manufacturing Market for Large and Very Large Companies, till 2030 (USD Million) Figure 18.31 Oligonucleotide Manufacturing Market: Distribution by Geography, 2021 and 2030 (USD Million) Figure 18.32 Oligonucleotide Manufacturing Market in North America, till 2030 (USD Million) Figure 18.33 Oligonucleotide Manufacturing Market in Europe, till 2030 (USD Million) Figure 18.34 Oligonucleotide Manufacturing Market in Asia-Pacific and Rest of the World, till 2030 (USD Million) Figure 20.1 Oligonucleotide Manufacturing: SWOT Analysis Figure 20.2 Comparison of SWOT Factors: Harvey Ball Analysis Figure 21.1 Survey Analysis: Distribution by Type of Organization Figure 21.2 Survey Analysis: Distribution by Location of Organization Figure 21.3 Survey Analysis: Distribution by Seniority Level of Respondents Figure 21.4 Survey Analysis: Distribution by Type of Offering Figure 21.5 Survey Analysis: Distribution by Application Figure 21.6 Survey Analysis: Distribution by Location of Manufacturing Facilities Figure 21.7 Survey Analysis: Distribution by Extent of Outsourcing Figure 21.8 Survey Analysis: Distribution by Current Market Opportunity Figure 23.1 Concluding Remarks: Overall Market Overview (1/3) Figure 23.2 Concluding Remarks: Overall Market Overview (2/3) Figure 23.3 Concluding Remarks: Overall Market Overview (3/3) Figure 23.4 Concluding Remarks: Recent Initiatives Figure 23.5 Concluding Remarks: Likely Partner Analysis Figure 23.6 Concluding Remarks: Capacity Analysis Figure 23.7 Concluding Remarks: Demand Analysis Figure 23.8 Concluding Remarks: Market Forecast and Opportunity Analysis (1/2) Figure 23.9 Concluding Remarks: Market Forecast and Opportunity Analysis (2/2)

LIST OF TABLES

Table 4.1 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: List of Industry Players Table 4.2 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Information on Location of Manufacturing Facilities and Regulatory Accreditations / Certifications Received Table 4.3 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Information on Type of Oligonucleotide Manufactured and Type of Offering Table 4.4 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Information on Type of Manufacturing Service(s) Offered Table 4.5 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Information on Type of Modification(s) Offered and Type of Purification Method(s) Used Table 5.1 Oligonucleotide Manufacturers Focused on Therapeutic Applications: List of Industry Players Table 5.2 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Information on Location of Manufacturing Facilities and Regulatory Accreditations / Certifications Received Table 5.3 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Information on Type of Oligonucleotide Manufactured and Type of Offering Table 5.4 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Information on Type of Manufacturing Service(s) Offered Table 5.5 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Information on Type of Modification(s) Offered and Type of Purification Method(s) Used Table 8.1 Ajinomoto Bio-Pharma Services: Key Highlights Table 8.2 Ajinomoto Bio-Pharma Services: Service Portfolio Table 8.3 Ajinomoto Bio-Pharma Services: Manufacturing Facilities and Capabilities Table 8.4 Ajinomoto Bio-Pharma Services: Recent Developments and Future Outlook Table 8.5 Integrated DNA Technologies: Key Highlights Table 8.6 Integrated DNA Technologies: Service Portfolio Table 8.7 Integrated DNA Technologies: Manufacturing Facilities and Capabilities Table 8.8 Integrated DNA Technologies: Recent Developments and Future Outlook Table 8.9 Sigma Aldrich: Key Highlights Table 8.10 Sigma Aldrich: Service Portfolio Table 8.11 Sigma Aldrich: Manufacturing Facilities and Capabilities Table 8.12 Sigma Aldrich: Recent Developments and Future Outlook Table 8.13 Thermo Fisher Scientific: Key Highlights Table 8.14 Thermo Fisher Scientific: Service Portfolio Table 8.15 Thermo Fisher Scientific: Manufacturing Facilities and Capabilities Table 8.16 Thermo Fisher Scientific: Recent Developments and Future Outlook Table 8.17 BioSpring: Key Highlights Table 8.18 BioSpring: Service Portfolio Table 8.19 BioSpring: Manufacturing Facilities and Capabilities Table 8.20 Kaneka Eurogentec: Key Highlights Table 8.21 Kaneka Eurogentec: Service Portfolio Table 8.22 Kaneka Eurogentec: Manufacturing Facilities and Capabilities Table 8.23 Microsynth: Key Highlights Table 8.24 Microsynth: Service Portfolio Table 8.25 Microsynth: Manufacturing Facilities and Capabilities Table 8.26 Sumitomo Chemical: Key Highlights Table 8.27 Sumitomo Chemical: Service Portfolio Table 8.28 Sumitomo Chemical: Manufacturing Facilities and Capabilities Table 9.1 Agilent Technologies: Key Highlights Table 9.2 Agilent Technologies: Service Portfolio Table 9.3 Agilent Technologies: Manufacturing Facilities and Capabilities Table 9.4 Agilent Technologies: Recent Developments and Future Outlook Table 9.5 Nitto Denko Avecia: Key Highlights Table 9.6 Nitto Denko Avecia: Service Portfolio Table 9.7 Nitto Denko Avecia: Manufacturing Facilities and Capabilities Table 9.8 Nitto Denko Avecia: Recent Developments and Future Outlook Table 9.9 TriLink Biotechnologies: Key Highlights Table 9.10 TriLink Biotechnologies: Service Portfolio Table 9.11 TriLink Biotechnologies: Manufacturing Facilities and Capabilities Table 9.12 TriLink Biotechnologies: Recent Developments and Future Outlook Table 9.13 CordenPharma: Key Highlights Table 9.14 CordenPharma: Service Portfolio Table 9.15 CordenPharma: Manufacturing Facilities and Capabilities Table 9.16 CordenPharma: Recent Developments and Future Outlook Table 9.17 LGC, Biosearch Technologies: Key Highlights Table 9.18 LGC, Biosearch Technologies: Service Portfolio Table 9.19 LGC, Biosearch Technologies: Manufacturing Facilities and Capabilities Table 9.20 LGC, Biosearch Technologies: Recent Developments and Future Outlook Table 9.21 Lonza: Key Highlights Table 9.22 Lonza: Service Portfolio Table 9.23 Lonza: Manufacturing Facilities and Capabilities Table 9.24 STA Pharmaceutical: Key Highlights Table 9.25 STA Pharmaceutical: Service Portfolio Table 9.26 STA Pharmaceutical: Manufacturing Facilities and Capabilities Table 9.27 STA Pharmaceutical: Recent Developments and Future Outlook Table 11.1 Big Pharma Players: List of Oligonucleotide Manufacturing Initiatives Table 12.1 Oligonucleotide Manufacturers: List of Partnerships, since 2014 Table 12.2 Oligonucleotide Manufacturers: Leading Players in Terms of Number of Partnerships Established with Different Types of Partners Table 12.3 Most Active Players: Geographical Distribution by Type of Partnership Model Table 12.4 Oligonucleotide Manufacturers: Key Value Drivers Table 13.1 Oligonucleotide Manufacturers: List of Expansions, since 2016 Table 14.1 Likely Partner Opportunities for Antisense Oligonucleotide Manufactures Table 14.2 Likely Partner Opportunities for siRNA Therapeutics Manufacturers Table 14.3 Likely Partner Opportunities for miRNA Therapeutics Manufacturers Table 14.4 Likely Partner Opportunities for shRNA and sshRNA Therapeutics Manufacturers Table 16.1 Global, Annual Oligonucleotide Manufacturing Capacity: Average Capacity by Size of Manufacturer (Sample Data Set) Table 16.2 Global, Annual Oligonucleotide Manufacturing Capacity: Distribution by Size of Manufacturer Table 17.1 Global, Annual Oligonucleotide Manufacturing Demand (Scenario 1), till 2030 (Kilograms) Table 17.2 Global, Annual Oligonucleotide Manufacturing Demand (Scenario 2), till 2030 (Kilograms) Table 17.3 Global, Annual Oligonucleotide Manufacturing Demand (Scenario 3), till 2030 (Kilograms) Table 21.1 Survey Analysis: Overview of Respondents Table 21.2 Survey Analysis: Information on Seniority Level of Respondents Table 21.3 Survey Analysis: Information on Type of Offering Table 21.4 Survey Analysis: Information on Application Table 21.5 Survey Analysis: Information on Oligonucleotide Manufacturing Capacity Table 21.6 Survey Analysis: Number and Location of Manufacturing Facilities Table 21.7 Survey Analysis: Information on Extent of Outsourcing Table 21.8 Survey Analysis: Current Market Opportunity (USD Billion) Table 22.1 Hanugen Therapeutics: Key Highlights Table 22.2 Axolabs: Key Highlights Table 22.1 IBA Life Sciences: Key Highlights Table 22.2 BianoScience: Key Highlights Table 24.1 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Year of Establishment Table 24.2 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Company Size Table 24.3 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Scale of Operation Table 24.4 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Company Size and Scale of Operation Table 24.5 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Headquarters Table 24.6 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Manufacturing Facilities (Country-wise) Table 24.7 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Regulatory Accreditations / Certifications Table 24.8 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Oligonucleotide Manufactured Table 24.9 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Offering Table 24.10 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Company Size and Type of Offering Table 24.11 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Oligonucleotide Manufactured and Type of Offering (Custom Synthesis) Table 24.12 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Manufacturing Service(s) Offered Table 24.13 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Modification(s) Offered Table 24.14 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Purification Method(s) Used Table 24.15 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Year of Establishment Table 24.16 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Company Size Table 24.17 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Scale of Operation Table 24.18 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Company Size and Scale of Operation Table 24.19 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Location of Headquarters Table 24.20 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Location of Manufacturing Facilities (Country-wise) Table 24.21 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Regulatory Accreditations / Certifications Table 24.22 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Oligonucleotide Manufactured Table 24.23 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Offering Table 24.24 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Company Size and Type of Offering Table 24.25 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Oligonucleotide Manufactured and Type of Offering (Modification) Table 24.26 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Manufacturing Service(s) Offered Table 24.27 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Modification(s) Offered Table 24.28 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Purification Method(s) Used Table 24.29 Ajinomoto Group: Annual Revenues (JPY Billion) Table 24.30 Thermo Fisher Scientific: Annual Revenues (USD Billion) Table 24.31 Kaneka Group: Annual Revenues (JPY Billion) Table 24.32 Sumitomo Chemical: Annual Revenues (JPY Billion) Table 24.33 Agilent Technologies: Annual Revenues (USD Billion) Table 24.34 Nitto Denko Avecia: Annual Revenues (JPY Billion) Table 24.35 TriLink Biotechnologies: Annual Revenues (USD Billion) Table 24.36 Lonza: Annual Revenues (CHF Billion) Table 24.37 STA Pharmaceutical: Annual Revenues (RMB Billion) Table 24.38 Big Pharma Initiatives: Cumulative Distribution by Year of Initiative, since 2014 Table 24.39 Big Pharma Initiatives: Distribution by Type of Initiative Table 24.40 Big Pharma Initiatives: Distribution by Type of Oligonucleotide Manufactured Table 24.41 Partnerships and Collaborations: Cumulative Distribution by Year of Partnership, since 2014 Table 24.42 Partnerships and Collaborations: Distribution by Type of Partnership Table 24.43 Partnerships and Collaborations: Year-wise Trend by Type of Partnership, since 2014 Table 24.44 Partnerships and Collaborations: Distribution by Type of Partner Table 24.45 Most Active Players: Distribution by Number of Partnerships Table 24.46 Most Active Players: Country-wise Distribution by Number of Partnerships Table 24.47 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution Table 24.48 Mergers and Acquisitions: Distribution by Year of Merger / Acquisition, since 2014 Table 24.49 Mergers and Acquisitions: Distribution by Type of Acquisition Table 24.50 Mergers and Acquisitions: Key Value Drivers Table 24.51 Recent Expansions: Cumulative Distribution by Year of Expansion, since 2016 Table 24.52 Recent Expansions: Distribution by Type of Expansion Table 24.53 Recent Expansions: Distribution by Type of Expansion and Purpose of Expansion Table 24.54 Recent Expansions: Distribution by Location of Facility Table 24.55 Recent Expansions: Distribution by Type of Expansion and Location of Facility Table 24.56 Recent Expansions: Distribution by Expanded Facility Area (Sq ft) Table 24.57 Recent Expansions: Distribution by Scale of Operation Table 24.58 Most Active Players: Distribution by Number of Expansions Table 24.59 Recent Expansions: Year-wise Trend by Geography, since 2015 Table 24.60 Recent Expansions: Distribution by Geography Table 24.61 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, since 2013 Table 24.62 Clinical Trial Analysis: Distribution by Trial Phase Table 24.63 Clinical Trial Analysis: Distribution by Type of Oligonucleotide Table 24.64 Clinical Trial Analysis: Distribution by Trial Phase and Type of Oligonucleotide Table 24.65 Clinical Trial Analysis: Distribution by Trial Registration Year and Type of Oligonucleotide, since 2013 Table 24.66 Clinical Trial Analysis: Distribution by Trial Recruitment Status Table 24.67 Clinical Trial Analysis: Distribution by Trial Registration Year and Recruitment Status Table 24.68 Clinical Trial Analysis: Distribution by Study Design Table 24.69 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials Table 24.70 Clinical Trial Analysis: Geographical Distribution by Trial Registration Year, since 2012 Table 24.71 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population Table 24.72 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year and Enrolled Patient Population, since 2012 Table 24.73 Clinical Trial Analysis: Geographical Distribution by Trial Registration Year and Trial Recruitment Status Table 24.74 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator Table 24.75 Most Active Industry Players: Distribution by Number of Registered Trials Table 24.76 Most Active Non-Industry Players: Distribution by Number of Registered Trials Table 20.77 Global, Annual Oligonucleotide Manufacturing Capacity: Distribution by Size of Manufacturers (Sample Data Set) Table 24.78 Global, Annual Oligonucleotide Manufacturing Capacity: Distribution by Size of Manufacturers (Kilograms) Table 24.79 Global, Annual Oligonucleotide Manufacturing Capacity: Distribution by Scale of Operation (Kilograms) Table 24.80 Global, Annual Oligonucleotide Manufacturing Capacity: Distribution by Location of Manufacturing Facility (Kilograms) Table 24.81 Global Demand for Oligonucleotide Manufacturing (Kilograms) Table 24.82 Global, Commercial Demand for Oligonucleotide Manufacturing (Kilograms) Table 24.83 Global, Commercial Demand for Oligonucleotide Manufacturing: Distribution by Type of Oligonucleotide (Kilograms) Table 24.84 Global, Commercial Demand for Oligonucleotide Manufacturing: Distribution by Target Therapeutic Area (Kilograms) Table 24.85 Global, Commercial Demand for Oligonucleotide Manufacturing: Distribution by Geography (Kilograms) Table 24.86 Global, Clinical Demand for Oligonucleotide Manufacturing (Kilograms) Table 24.87 Global, Clinical Demand for Oligonucleotide Manufacturing: Distribution by Type of Oligonucleotide (Kilograms) Table 24.88 Global, Clinical Demand for Oligonucleotide Manufacturing: Distribution by Phase of Development (Kilograms) Table 24.89 Global, Clinical Demand for Oligonucleotide Manufacturing: Distribution by Target Therapeutic Area (Kilograms) Table 24.90 Global, Clinical Demand for Oligonucleotide Manufacturing: Distribution by Geography (Kilograms) Table 20.91 Global Oligonucleotide Manufacturing: Demand and Supply (Scenario 1), till 2030 Table 24.92 Global Oligonucleotide Manufacturing: Demand and Supply (Scenario 2), till 2030 Table 24.93 Global Oligonucleotide Manufacturing: Demand and Supply (Scenario 3), till 2030 Table 20.94 Global Oligonucleotide Contract Manufacturing Market, Conservative, Base and Optimistic, till 2030 (USD Million) Table 20.95 Oligonucleotide Manufacturing Market for Research and Diagnostics Applications, Conservative, Base and Optimistic, till 2030 (USD Million) Table 20.96 Oligonucleotide Manufacturing Market for Therapeutic Applications, Conservative, Base and Optimistic, till 2030 (USD Million) Table 20.97 Oligonucleotide Manufacturing Market: Distribution by Type of Oligonucleotide Manufactured, 2021 and 2030 Table 20.98 Oligonucleotide Manufacturing Market for Antisense Oligonucleotides, Conservative, Base and Optimistic, till 2030 (USD Million) Table 20.99 Oligonucleotide Manufacturing Market for miRNA, Conservative, Base and Optimistic, till 2030 (USD Million) Table 20.100 Oligonucleotide Manufacturing Market for DNA Oligonucleotides, Conservative, Base and Optimistic, till 2030 (USD Million) Table 20.101 Oligonucleotide Manufacturing Market for siRNA, Conservative, Base and Optimistic, till 2030 (USD Million) Table 20.102 Oligonucleotide Manufacturing Market for Phosphorothioate Oligonucleotides, Conservative, Base and Optimistic, till 2030 (USD Million) Table 20.103 Oligonucleotide Manufacturing Market for Decoy Oligonucleotides, Conservative, Base and Optimistic, till 2030 (USD Million) Table 20.104 Oligonucleotide Manufacturing Market for Clinical Scale Operations, Conservative, Base and Optimistic, till 2030 (USD Million) Table 20.105 Oligonucleotide Manufacturing Market for Commercial Scale Operations, Conservative, Base and Optimistic, till 2030 (USD Million) Table 20.106 Oligonucleotide Manufacturing Market for Active Pharmaceutical Ingredients, Conservative, Base and Optimistic, till 2030 (USD Million) Table 20.107 Oligonucleotide Manufacturing Market for Finished Dosage Form, Conservative, Base and Optimistic, till 2030 (USD Million) Table 20.108 Oligonucleotide Manufacturing Market for In-house Manufacturing Operations, Conservative, Base and Optimistic, till 2030 (USD Million) Table 20.109 Oligonucleotide Manufacturing Market for Outsourced Operations, Conservative, Base and Optimistic, till 2030 (USD Million) Table 20.110 Oligonucleotide Manufacturing Market: Distribution by Target Therapeutic Area, 2025 and 2030 (USD Million) Table 20.111 Oligonucleotide Manufacturing Market for Cardiovascular Disorders, Conservative, Base and Optimistic, till 2030 (USD Million) Table 20.112 Oligonucleotide Manufacturing Market for CNS Disorders, Conservative, Base and Optimistic, till 2030 (USD Million) Table 20.113 Oligonucleotide Manufacturing Market for Genetic Disorders, Conservative, Base and Optimistic, till 2030 (USD Million) Table 20.114 Oligonucleotide Manufacturing Market for Hematological Diseases, Conservative, Base and Optimistic, till 2030 (USD Million) Table 20.115 Oligonucleotide Manufacturing Market for Infectious Diseases, Conservative, Base and Optimistic, till 2030 (USD Million) Table 20.116 Oligonucleotide Manufacturing Market for Metabolic Disorders, Conservative, Base and Optimistic, till 2030 (USD Million) Table 20.117 Oligonucleotide Manufacturing Market for Neuromuscular Disorders, Conservative, Base and Optimistic, till 2030 (USD Million) Table 20.118 Oligonucleotide Manufacturing Market for Oncological Disorders, Conservative, Base and Optimistic, till 2030 (USD Million) Table 20.119 Oligonucleotide Manufacturing Market for Ophthalmic Disorders, Conservative, Base and Optimistic, 2021till 2030 (USD Million) Table 20.120 Oligonucleotide Manufacturing Market for Other Disorders, Conservative, Base and Optimistic, till 2030 (USD Million) Table 20.121 Oligonucleotide Manufacturing Market for Small Companies, Conservative, Base and Optimistic, till 2030 (USD Million) Table 20.122 Oligonucleotide Manufacturing Market for Mid-sized Companies, Conservative, Base and Optimistic, till 2030 (USD Million) Table 20.123 Oligonucleotide Manufacturing Market for Large and Very Large Companies, Conservative, Base and Optimistic, till 2030 (USD Million) Table 20.124 Oligonucleotide Manufacturing Market: Distribution by Geography, 2021 and 2030 (USD Million) Table 20.125 Oligonucleotide Manufacturing Market in North America, Conservative, Base and Optimistic, till 2030 (USD Million) Table 20.126 Oligonucleotide Manufacturing Market in Europe, Conservative, Base and Optimistic, till 2030 (USD Million) Table 20.127 Oligonucleotide Manufacturing Market in Asia-Pacific and Rest of the World, Conservative, Base and Optimistic, till 2030 (USD Million) Table 24.128 Survey Insights: Distribution by Type of Organization Table 24.129 Survey Insights: Distribution by Location of Organization Table 24.130 Survey Insights: Distribution by Seniority Level of Respondents Table 24.131 Survey Insights: Distribution by Type of Offering Table 24.132 Survey Insights: Distribution by Application Table 24.133 Survey Insights: Distribution by Location of Manufacturing Facilities Table 24.134 Survey Insights: Distribution by Extent of Outsourcing Table 24.135 Survey Insights: Distribution by Current Market Opportunity

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

Agilent Technologies
Ajinomoto Bio-Pharma Services
CordenPharma
Creative Biolabs
Ella Biotech
Eurofins Genomics
Future synthesis
Integrated DNA Technologies
Kaneka Eurogentec
LGC Biosearch Technologies
Microsynth
Nitto Avecia
Merck
Ribo Biotechnology
STA Pharmaceutical
Sumitomo Chemical
Thermo Fisher Scientific
TriLink Biotechnologies

Methodology

LOADING...

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€4595EUR$4,799USD£3,855GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€7659EUR$7,999USD£6,426GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€15320EUR$15,999USD£12,852GBP